Página 5 - Melhores Consulta Online com Oncologista médicos - TOP-114 médicos

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

O médico é especializado em câncer de mama e tratamento endócrino, focando em superar a resistência à terapia hormonal durante a doença adjuvante e metastática. Envolvido ativamente em estudos de fase 1, 2 e 3 para câncer de mama e melanoma, o médico contribuiu para a aprovação de novos medicamentos, incluindo inibidores de cdk4/6 como palbociclib e ribociclib para câncer de mama metastático, e tratamentos de imunoterapia como Pembrolizumab, Nivolumab e Ipilimumab para melanoma. O médico é membro da Unidade de Câncer de Mama e da Unidade de Melanoma no Hospital Universitário Vall d’Hebron e no Instituto de Oncologia Vall d’Hebron.<\/p>

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

O médico recebeu educação médica superior na Universidade Hebraica e completou residência em medicina interna e gastroenterologia no Hospital Universitário Hadassah. Um estágio em doenças hepáticas foi concluído na Escola de Medicina Sinai em Nova York. O médico é especialista no tratamento de doenças hepáticas, liderando a unidade de doenças hepáticas no Centro Médico Hadassah. Ele é membro de várias associações internacionais de estudo do fígado e do conselho editorial da Clinical Science. O médico é autor de numerosos artigos e recebeu múltiplos prêmios, incluindo o Prêmio Hadassah e prêmios da Associação Israelense de Gastroenterologia e Hepatologia.<\/p>

O médico é um cientista clínico com experiência na aplicação clínica de descobertas laboratoriais no câncer de mama, focando na expressão gênica e subtipos moleculares. O médico projeta e lidera ensaios clínicos para novos medicamentos e abordagens na SOLTI, um grupo cooperativo espanhol de câncer de mama.<\/p>

Graduando-se com um MD da Universidade de Barcelona em 2003, o médico completou uma bolsa de oncologia médica no Instituto de Oncologia Vall d'Hebron e pesquisa pós-doutoral na Universidade da Carolina do Norte.<\/p>

Atualmente, o médico lidera o Grupo de Genômica Translacional e Terapias Alvo em Tumores Sólidos no IDIBAPS e é o Presidente do Conselho de Administração da SOLTI. O médico co-fundou a Reveal Genomics e possui três patentes.<\/p>

Com mais de 160 publicações e um índice H de 51, o médico foi citado 13.479 vezes e apresentou 95 comunicações internacionalmente.<\/p>

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Key facts and achievements

• - More than 20 years of experience in the treatment of complex pathologies of the brain using Gamma Knife radiosurgery , including functional disorders and tumor diseases.
• -Works in a team with Dr. Roberto Martinez Alvarez , a world-leading neurosurgeon and Gamma Knife specialist, providing a unique multidisciplinary approach to patient care.
• - International experience : Studied and collaborated with leading global institutions, including the Gregorio Marañon in Madrid and the Gustave Roussy Institute in Paris.

Specialization

• More than 7,000 patients have been treated in the Radiosurgery Department, including:
• - Benign tumors : meningiomas, schwannomas, pituitary adenomas.
• - Malignant pathologies : brain metastases and CNS tumors.
• - Vascular pathologies : arteriovenous malformations, cavernomas and fistulas.
• - Functional disorders : refractory epilepsy, tremor, trigeminal neuralgia and obsessive-compulsive disorder.

Scientific and professional activities

• - Member of the international Gamma Knife Consortium , led by the University of Pittsburgh .
• - Author of scientific research and protocols for the treatment of cancer using radiotherapy.
• - Participated in the development of the innovative project "Fusion of Medical Images" as part of oncology research.

Experience

2002-present | Attached to the Department of Gamma Radiosurgery and Functional Neurosurgery of Ruber International Hospital.

2002-2007 | Assistant, Department of Radiation Oncology, Ruber International Hospital.

2002| Medical Affairs Manager Medical Department Janssen-Cilag, SA Madrid

Qualification

2012|Doctor of Medicine and Surgery Madrid. Department of Surgery, Autonomous University of Madrid. Spain

2001 | Specialist in Radiation Oncology at the Gregorio Marañón University Hospital in Madrid. Training completed at the Gustave-Roussy Institute in Paris in 2000.

1995 | Graduate of the Faculty of Medicine and Surgery, Complutense University of Madrid. Spain.

2016-present | Member of the Ruber International Hospital Gamma Knife Radiosurgery Team, International Gamma Knife Consortium: Led by the Pittsburgh Hospital.

1999-2000| Project Manager: "Protocol for Pamidronate Treatment of Breast Cancer Patients with Predominantly Lytic Bone Metastases"

1999 | GICOR Study: "Incidence of Anemia in Patients Receiving Radiation Therapy"

1999 | GICOR study: "Androgen deprivation protocol associated with radiation therapy for localized high-risk prostate cancer"

1997-2001|Participant (collaborator) in the research project (FIS FELLOWSHIP): "Multimodal fusion of medical images in oncology" at HGU Gregorio Marañon. Project leader: Dr. Desco Menéndez.

Teaching :

2018-present|Professor of the International Master of Radiosurgery of the Central Nervous System at the Complutense University of Madrid.

2020-present|Professor at the School of Radiosurgery of the Spanish Society of Neurosurgeons.

2017-2019|Professor of the Master of Radiosurgery and Clinical Stereotactic Radiotherapy of the Spanish Society of Radiation Oncology.

2017 - 2022| Member of the Dissertation Committee in Radiosurgery three times at the Autonomous University of Madrid and the Complutense University of Madrid.

2011-2012|Professor, International Master's Program in Advanced Technological Applications in Radiation Oncology, 3rd ed.

2001-2002|Associate Professor of Dentistry at the Alfonso X El Sabio University.

1998 - 2001|Professor of the secondary school I.E. Technical and vocational school of health K.A.M. (Radiation oncology technicians and archival technicians).

Publications

2022|Stereotactic radiosurgery of obsessive-compulsive disorders. Chapter. 25. Book: Intracranial stereotactic radiosurgery. ed. 2022. Pages: 251-256.

2022|Active monitoring and stereotactic radiosurgery provide a low risk of symptoms associated with incident frontobasal meningioma, but stereotactic radiosurgery provides better radiological control – a subanalysis of the IMPASSE trial. Cancers 2022; 14(5).1300. https://doi.org/10.3390/cancers14164047

2022|Stereotactic radiosurgery for Kuss grade IV vestibular schwannoma: a multi-institutional study. Journal of Neurosurgery. 2022 Jun 3; DOI: 10.3171/2022.4.JNS22203.

2022|Stereotactic radiosurgery for Rathke's cleft cyst: an international multicenter study. J Neurosurg 137: 1041–1046, 2022. DOI: 10.3171/2021.12.JNS212108.

2021|Surgery and radiosurgery in autism: a retrospective study on 10 patients. Stereotactic Function Neurosurgery. 2021;99(6):474–483. 15.

Presentations

2019| "Other indications in malignant tumor pathology" Cranial Radiosurgery Conference. Valencia 2019.

2018| Gamma Knife Radiosurgery: Concept, Equipment and Treatment Description I Scientific Conference on Gamma Knife Radiosurgery, Madrid, 2018

2018|Radiotherapy and protons in children. XX meeting of the SENEC Working Group on Neuro-Oncology:. Madrid.

2015| "Visualization monitoring of response and complications of brain treatment". XVIII National Congress of S.E.O.R. Valencia

2015 | Gamma Knife Radiosurgery in the Treatment of Refractory Epilepsy Associated with Nodular Heterotopia: Long-Term Safety and Efficacy. Congress of the Spanish Society of Neurology.

Communities it belongs to:

-SER, Spanish Society of Radiosurgery (she currently serves on the Board of Directors as Treasurer)

-SEOR, Spanish Society of Oncological Radiotherapy: Working Groups "Brain Tumors (NEUROONCOR)" and "Radiation Oncology Activities in the Private Sector"

-SSRI, International Society for Stereotactic Radiosurgery

- Member of the Oncology Group of the Spanish Society of Neurosurgery (SENEC).

Dr. Nuria Martínez Moreno , working in tandem with Dr. Roberto Martínez Álvarez, combines expert oncology knowledge and high-precision radiosurgery technology , providing patients with the most advanced and effective treatment in Spain.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

O médico concentrou sua pesquisa em síndromes neurológicas paraneoplásicas, liderando um painel que estabeleceu critérios diagnósticos. Seu trabalho confirmou a hipótese imunológica que liga tumores a disfunções neurológicas autoimunes, com anticorpos identificados por ele agora essenciais para o diagnóstico.<\/p>

Clinicamente, o médico se especializa no diagnóstico e manejo de gliomas, linfomas cerebrais primários e neurotoxicidades relacionadas ao tratamento do câncer. Os interesses recentes incluem complicações neurológicas de inibidores de pontos de controle imunológico e transplante de células-tronco hematopoéticas.<\/p>

Ele possui um MD e PhD da Universitat Autónoma de Barcelona, completou uma residência em neurologia em Barcelona e uma bolsa de estudos em neuro-oncologia no Memorial Sloan-Kettering Cancer Center.<\/p>

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

O Dr. Abu Shamsiya Rami Nuamanovych é especialista em cirurgia geral e laparoscópica, oncologia e diagnósticos por ultrassom. Ele é Candidato a Doutor em Ciências Médicas, professor associado e médico da mais alta categoria. O Dr. Nuamanovych é membro da Associação Ucraniana de Cirurgiões Bariátricos e da Organização Mundial de Cirurgiões Bariátricos (IFSO).

Ele atua como consultor da OMS em cirurgia laparoscópica. É também Presidente da Associação de Médicos Árabes da Ucrânia. O Dr. Nuamanovych realizou milhares de cirurgias, incluindo reparo de hérnias, procedimentos bariátricos e operações oncológicas. Suas habilidades são reconhecidas internacionalmente. Ele fala inglês e árabe fluentemente.

O médico completou a formação de especialização em Oncologia de Radiação na Faculdade de Medicina da Universidade de Marmara de 2012 a 2016. Antes disso, o médico completou uma graduação em Medicina, ministrada em inglês, na mesma instituição de 2004 a 2011. O médico tem uma sólida base em educação médica, começando com a educação secundária na Escola Número Dezesseis de Shirvan no Azerbaijão de 1998 a 2004.<\/p>

Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

O médico se especializa em uma ampla gama de tratamentos cirúrgicos em urologia, incluindo todos os tipos de operações. Eles gerenciam serviços médicos gerais e fornecem avaliações especializadas em situações clínicas complexas. O médico está ativamente envolvido no atendimento ao paciente através de recepções em policlínicas e oferece "segundas opiniões" em casos desafiadores. Eles também estão envolvidos na organização e facilitação de master classes, workshops e webinars.<\/p>

Proficiente em técnicas avançadas como enucleação e vaporização a laser da próstata, dissecção a laser de tumores da bexiga e várias formas de litotripsia, o médico também realiza procedimentos complexos como nefrectomia radical, pielolitotomia e ureterolitotomia, entre outros.<\/p>

O médico completou um MBBS na MIMER, Pune, e um MS na GMC Panaji. O treinamento adicional incluiu uma bolsa de dois anos em Oncologia Cirúrgica no Tata Medical Centre, Kolkata, com foco em Câncer Gastrointestinal. No Tata Medical Center, o médico atuou como Co-investigador Principal em vários projetos de pesquisa originais. Após isso, o médico trabalhou como Professor Assistente no Instituto Estadual do Câncer e no Hospital do Câncer do Governo, Aurangabad. Com mais de 10 anos de experiência, o médico realizou com sucesso mais de 10.000 cirurgias de grande porte e publicou vários artigos Nacionais e Internacionais. Especializa-se em Cirurgias de Câncer Minimamente Invasivas.<\/p>

O médico recebeu treinamento em Oncologia Cirúrgica no Tata Memorial Hospital, Mumbai, e completou o MRCS no Royal College of Surgeons, Edimburgo. Iniciando a prática em 2000, o médico fundou o Curie Manavata Cancer Centre em 2007. Com 19 anos de experiência, o médico realizou mais de 50.000 cirurgias de câncer e participou de mais de 200 ensaios clínicos. O médico é autor publicado com numerosas publicações internacionais e nacionais. Especializando-se em Oncologia Cirúrgica de Mama e Torácica, o médico é professor de DNB Superspecialty Surgical Oncology e Breast Surgery na MUHS.<\/p>

O médico conduziu uma pesquisa significativa sobre a dose efetiva cumulativa de radiação de tomografias computadorizadas de tórax em pacientes com COVID-19. Este trabalho destaca a importância de aderir às diretrizes para minimizar a exposição desnecessária, refletindo um compromisso com a segurança do paciente e a prática baseada em evidências.<\/p>

O médico é um especialista experiente em hematologia oncológica infantil e um neurocirurgião pediátrico líder na Espanha. Com mais de 30 anos de experiência prática, o médico lidera a Unidade de Hematologia e Oncologia Pediátrica no HM Hospitales, focando em doenças hematológicas e cancerígenas graves em crianças e adolescentes.<\/p>

O médico é especializado no diagnóstico e tratamento de distúrbios hematológicos e cancerígenos, particularmente nos sistemas eritrocitário, mieloide e linfoide. O médico atua como consultor da OMS e da UNESCO e está envolvido em atividades de ensino e pesquisa.<\/p>

As credenciais educacionais incluem diplomas da Universidad Complutense de Madrid, da Universidade de Barcelona e da Universidade de Maryland.<\/p>